The Protocol Review and Monitoring System (PRMS) for the NYUCI is responsible for evaluating the scientific merit of all cancer-related population-based, translational and clinical research studies that take place on the NYU Langone Medical Center campus and those of its strategic alliances. Once the clinical protocol documentation has been completed, the PRMS provides a forum for multi-level review, confirming the scientific merit and programmatic fit. After the NYU School of Medicine Institutional Review Board (IRB) approves the protocol, the PRMS monitors for scientific progress and performance. A central core of the PRMS is the Protocol Review and Monitoring Committee (PRMC). PRMC membership is drawn from the membership of the NYUCI based on expertise in the development and conduct of clinical trials, as well as leadership in key clinical positions. Physician members of the committee represent the different subspecialties providing care and participating in clinical research within the NYUCI. In addition, the PRMC includes bench scientists, biostatisticians, members of the administrative staff of the NYUCI, oncology nursing and the investigational pharmacy. PRMC approval is required for IRB submission and approval. PRMC review includes the underlying hypothesis, design, and the likelihood that the trial will lead to clinically meaningful results. The PRMC monitors accrual yearly and requires that investigators provide a formal plan to increase enrollment if accrual is <50% of projected target. The PRMC has the authority to close under-accruing trials. Investigator initiated studies are the highest priority for the NYUCI especially those involving novel agents based on laboratory results from NYUCI basic and/or translational scientists. The number of reviewed protocols has increases since the last review. In 2011, PRMC reviewed 126 protocols as compared to 94 in 2007.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016087-33
Application #
8436454
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-03-01
Project End
2018-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
33
Fiscal Year
2013
Total Cost
$22,887
Indirect Cost
$9,384
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Pham, Alissa M; Santa Maria, Felicia Gilfoy; Lahiri, Tanaya et al. (2016) PKR Transduces MDA5-Dependent Signals for Type I IFN Induction. PLoS Pathog 12:e1005489
Kim, Sungheon G; Feng, Li; Grimm, Robert et al. (2016) Influence of temporal regularization and radial undersampling factor on compressed sensing reconstruction in dynamic contrast enhanced MRI of the breast. J Magn Reson Imaging 43:261-9
Zakhar, Joseph; Amrock, Stephen M; Weitzman, Michael (2016) Passive and Active Tobacco Exposure and Children's Lipid Profiles. Nicotine Tob Res 18:982-7
Vogelsang, Matjaz; Martinez, Carlos N; Rendleman, Justin et al. (2016) The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis. Clin Cancer Res 22:3268-80
Pylayeva-Gupta, Yuliya; Das, Shipra; Handler, Jesse S et al. (2016) IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. Cancer Discov 6:247-55
Lau, Colleen M; Nish, Simone A; Yogev, Nir et al. (2016) Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses. J Exp Med 213:415-31
Reynaud, Olivier; Winters, Kerryanne Veronica; Hoang, Dung Minh et al. (2016) Pulsed and oscillating gradient MRI for assessment of cell size and extracellular space (POMACE) in mouse gliomas. NMR Biomed 29:1350-63
Domènech-Estévez, Enric; Baloui, Hasna; Meng, Xiaosong et al. (2016) Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS. J Neurosci 36:4506-21
Abdu, Yusuff; Maniscalco, Chelsea; Heddleston, John M et al. (2016) Developmentally programmed germ cell remodelling by endodermal cell cannibalism. Nat Cell Biol 18:1302-1310
Canino, Claudia; Cioce, Mario (2016) Isolation of Chemoresistant Cell Subpopulations. Methods Mol Biol 1379:139-50

Showing the most recent 10 out of 878 publications